Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407763 | 0.86 | KMT2A (1.00) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL13407753 | 0.84 | MAPT (0.78) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL13407764 | 0.83 | POLB (1.00) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2923717 | 0.83 | POLB (0.56) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2918271 | 0.82 | POLB (0.69) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2924510 | 0.82 | MAPT (0.62) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2920564 | 0.81 | ALDH1A1 (0.72) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL4146568 | 0.81 | MAPT (0.64) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2924778 | 0.81 | KDM4E (0.63) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL2920121 | 0.80 | MAPT (0.60) | ALDH1A1LMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| US-20100087453-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-08 | — | — | US | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087453-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | ASAH2, LITAF, CYP27A1 | ALDH1A1 1121/4885LMNA 225/4885MEN1 2131/4885 |
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | ALDH1A1 229/4885LMNA 4510/4885MEN1 2028/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | ALDH1A1 229/4885LMNA 4510/4885MEN1 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.